FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to mini-protein USH2A, which, with a small size, which enables delivery as a part of viral vectors, preserves domains of the full-length protein LamGL, LamNT, EGF Lam, FN3 and PDZ-binding motif, which are necessary for the functioning of the USH2A protein. Also disclosed is a nucleic acid coding a mini-protein USH2A, an expression vector and the use of said vector in a gene therapy of type II Usher syndrome.
EFFECT: invention is effective for stable and high expression of USH2A mini-protein.
13 cl, 11 dwg, 8 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CODON-OPTIMISED HAIPL1-ENCODING NUCLEOTIDE SEQUENCE AND EXPRESSION VECTOR CONTAINING SAID SEQUENCE | 2021 |
|
RU2785621C1 |
| MITOCHONDRIAL LOCALIZATION PEPTIDE, NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE CONTAINING ITS EXPRESSION VECTOR AND ITS USE | 2023 |
|
RU2817420C1 |
| NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE | 2023 |
|
RU2809065C1 |
| ADENO-ASSOCIATED VIRAL VECTOR CONSISTING OF CAPSID PROTEINS PHP_B, NUCLEIC ACID CODING SMN PROTEIN, AND USE THEREOF | 2022 |
|
RU2833225C2 |
| NUCLEIC ACID DESIGNED TO REDUCE MAMMALIAN BODY WEIGHT, EXPRESSION VECTOR FOR EXPRESSION IN MAMMALIAN CELLS, METHOD FOR ITS DELIVERY AND METHOD FOR REDUCING MAMMALIAN BODY WEIGHT | 2023 |
|
RU2810191C1 |
| F-PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS AND ITS USE | 2007 |
|
RU2464316C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
| GENE THERAPY OF OPHTHALMIC DISORDERS | 2016 |
|
RU2762747C2 |
| NUCLEIC ACID CONTAINING PRDM16 GENE SEQUENCE FOR REDUCING BODY WEIGHT OF MAMMAL, EXPRESSION VECTOR FOR EXPRESSION IN MAMMALIAN CELLS, METHOD FOR DELIVERY THEREOF AND METHOD FOR REDUCING BODY WEIGHT IN MAMMAL | 2024 |
|
RU2834035C1 |
| NUCLEIC ACID HAVING PROMOTER ACTIVITY AND ITS USE | 2022 |
|
RU2818112C2 |
